Faculté de Médecine
1, rue Gaston Veil
144 articles with OSE Immunotherapeutics
Phase 3 Clinical Trial of Tedopi®: OSE Immunotherapeutics Announces Positive Top-Line Results for Step-1 of its trial ‘Atalante 1’ in Non-Small Cell Lung Cancer
Step-1 primary endpoint met: 12-month survival rate in Tedopi® treated patients;
OSE Immunotherapeutics Reports 2019 Financial Results and Provides Business Update Expectations for Potential Impact of COVID-19 on the Company’s Clinical Development Activities
OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today reported its consolidated annual financial results for 2019 and provided an update on key achievements, as well as the company’s outlook for its agonist and antagonist immunotherapies for cancers and autoimmune diseases.
3/19/2020Companies from across the globe provide updates on their business operations and pipeline development.
OSE Immunotherapeutics and Servier Amend the Global Licensing Option Agreement for IL-7R Antagonist OSE-127 in Autoimmune Diseases
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) and Servier today announced the execution of an amendment to the two-step global licensing option agreement for exclusive global rights to interleukin-7 receptor (IL-7R) antagonist OSE-127.
OSE Immunotherapeutics and MAbSilico Announce Artificial Intelligence Antibody Drug Development Collaboration
Agreement capitalizes on artificial intelligence and deep learning to develop therapeutic monoclonal antibodies, including novel bispecific antibodies (BiCKI® platform)
OSE Immunotherapeutics Announces Artificial Intelligence Antibody Drug Development Collaboration with MAbSilico
Agreement capitalizes on artificial intelligence and deep learning to develop therapeutic monoclonal antibodies, including novel bispecific antibodies (BiCKI® platform) Collaboration runs for 3 years and will be used for 6 antibody programs NANTES, France, Feb. 12, 2020 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), today announced a new collaboration agreement with deep technology innovative start-up MAbSilico , located in Tours, France, to use artificia
OSE Immunotherapeutics Announces Issuance of a New Patent in Japan for Tedopi® on Inducing Early T-Lymphocyte Memory ResponseFurther Strengthens Global Intellectual Property Portfolio for Tedopi® in Immuno-Oncology
OSE Immunotherapeutics announced that the Japanese Patent Office has issued a new patent family related to Tedopi®, a combination of neoepitopes, protecting the product’s method for inducing early T-lymphocyte memory response for use in the treatment of cancer in HLA-A2 positive patients.
12/9/2019It was, as usual, a pretty busy week in clinical trial news. Here’s a look.
12/5/2019Companies from across the globe provide updates on their business and pipelines.
OSE Immunotherapeutics Announces Positive Results from Phase 1 Clinical Study of Anti-IL-7 Receptor Antagonist OSE-127
OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced completion and positive results from the Phase 1 study of OSE-127, a humanized monoclonal antibody with a differentiated mechanism of action as a full-antagonist of the CD127 receptor, the alpha chain of the interleukin-7 receptor (IL-7R). OSE-127 has been shown in previous studies to induce a powerful antagonistic effect on effector T lymphocytes responsible for causing autoimmune diseases.
OSE Immunotherapeutics and HalioDx Collaborate to Perform Immune Biomarker Exploratory Work during Atalante 1 Phase 3 Clinical Trial of Tedopi® in Non-Small Cell Lung Cancer
OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), a clinical-stage biotechnology company focused on developing innovative immunotherapies, and HalioDx, the immuno-oncology diagnostic company, today announced a collaboration to conduct a translational investigation of immune biomarkers as part of the ongoing Phase 3 clinical trial of neoepitope combination Tedopi® in non-small cell lung cancer (NSCLC) patients.
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
OSE Immunotherapeutics Announces Licensing Deal for Neoepitope Combination Tedopi® in Korea with Chong Kun Dang Pharmaceutical Corporation
OSE Immunotherapeutics, announced a new licensing deal with Chong Kun Dang Pharmaceutical Corporation for Tedopi®, a combination of neoepitopes selected and optimized from five tumor antigens shown to generate a specific response of cytotoxic T cells versus cancer cells expressing at least one of these tumor associated antigens and an associated T-helper cell response, for potential registration and commercialization in Korea.
9/5/2019Companies from across Europe and Asia share updates on their business and pipelines.
7/25/2019Biotech and pharma companies from across the globe provide updates on company strategy and pipeline developments.
7/18/2019Pharma and biotech companies from across the globe provide updates on their pipelines and corporate strategy.
12/26/2018Companies closed out the year with a number of appointments and hires to strengthen their leadership teams, including changes at the FDA, Melinta, CLSA, Virion, and more.
OSE Immunotherapeutics Announces Publication in Nature Communications on Anti-IL-7 Receptor Antagonist (OSE-127)
Full Antagonist Mechanism of Action Demonstrated In Vivo
Boehringer Ingelheim and OSE Immunotherapeutics signed a collaboration and license deal to jointly develop OSE-172 for myeloid cancers.
OSE Immunotherapeutics Receives Notice of Allowance for New Patent by U.S. Patent and Trademark Office that Further Strengthens Intellectual Property Portfolio Around Tedopi in Immuno-Oncology Applications
The new patent extends the U.S. protection of Tedopi to several combinations of neoepitopes (peptides from various tumourous antigens optimized to bind strongly with HLA-A2 and T lymphocyte receptors) for use in cancer treatment.